Ling Yue

Ling Yue

Auto-generated profile, based on publicly available information

Ling Yue

Rensselaer Polytechnic Institute, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2023 in Nature Computational Science
Verified
Journal Article
Closed access
PDF file
YZYongqi Zhang
Yongqi Zhang
QYQuanming Yao
Quanming Yao
LYLing Yue
Ling Yue
XWXian Wu
Xian Wu
ZZZiheng Zhang
Ziheng Zhang
YZYefeng Zheng
Yefeng Zheng

22 November 2024
Verified
Conference Paper
Open access
LYLing Yue
Ling Yue
SXSixue Xing
Sixue Xing
JCJintai Chen
Jintai Chen
TFTianfan Fu
Tianfan Fu
Large Language Models (LLMs) and multi-agent systems have shown impressive capabilities in natural language tasks but face challenges in clinical trial applications, primarily due to limited access to external knowledge. Recognizing the potential of advanced clinical trial tools that aggregate and predict based on the latest medical data, we propose an integrated solution to enhance their accessibility and utility. We introduce Clinical Agent System (ClinicalAgent), a clinical multi-agent system designed for clinical trial tasks, leveraging GPT-4, multi-agent architectures, LEAST-TO-MOST, and ReAct reasoning technology. This integration not only boosts LLM performance in clinical contexts but also introduces novel functionalities. The proposed method achieves competitive predictive performance in clinical trial outcome prediction (0.7908 PR-AUC), obtaining a 0.3326 improvement over the standard prompt Method. Publicly available code can be found at https://github.com/LeoYML/clinical-agent.

22 November 2024
Verified
Conference Paper
Open access
LYLing Yue
Ling Yue
SXSixue Xing
Sixue Xing
JCJintai Chen
Jintai Chen
TFTianfan Fu
Tianfan Fu
Clinical trials need to recruit a sufficient number of volunteer patients to demonstrate the statistical power of the treatment (e.g., a new drug) in curing a certain disease. Clinical trial recruitment has a significant impact on trial success. Forecasting whether the recruitment process would be successful before we run the trial would save many resources and time. This paper develops a novel deep & cross network with large language model (LLM)-augmented text feature that learns semantic information from trial eligibility criteria and predicts enrollment success. The proposed method enables interpretability by understanding which sentence/word in eligibility criteria contributes heavily to prediction. We also demonstrate the empirical superiority of the proposed method (0.7002 PR-AUC) over a bunch of well-established machine learning methods. The code and curated dataset are publicly available at https://github.com/LeoYML/TrialEnroll.

22 November 2024
Verified
Conference Paper
Open access
LYLing Yue
Ling Yue
SXSixue Xing
Sixue Xing
JLJonathan Li
Jonathan Li
ZIZabirul Islam
Zabirul Islam
BXBolun Xia
Bolun Xia
TFTianfan Fu
Tianfan Fu
The clinical trial process is crucial for ensuring the safety and efficacy of new pharmaceuticals but is often hindered by lengthy durations, high costs, and labor-intensive processes. These challenges delay the availability of life-saving treatments and increase financial burdens on pharmaceutical companies, with average costs exceeding 2 billion dollars per trial. Efficient management of trial timelines is essential to control budgets and improve the economic feasibility of research. To address these challenges, we introduce TrialDura, an innovative machine learning-based framework designed to predict the duration of clinical trials. TrialDura utilizes a multimodal approach, incorporating diverse data sources such as disease names, drug molecules, trial phases, and detailed eligibility criteria. These elements are encoded using Bio-BERT embeddings, which are specifically tuned for biomedical contexts to provide a comprehensive semantic understanding of the trial data. The model employs a hierarchical attention mechanism that effectively integrates these embeddings, capturing complex interactions between different data modalities to enhance prediction accuracy. Our extensive experiments demonstrate that TrialDura significantly outperforms existing models, achieving a mean absolute error (MAE) of 1.04 years and a root mean square error (RMSE) of 1.39 years. This performance underscores the model's ability to deliver more precise predictions of trial durations, which can facilitate better planning and resource allocation in clinical research. By providing insights into expected trial timelines, TrialDura aids in optimizing trial management strategies, potentially reducing costs and accelerating the development of new treatments. Furthermore, TrialDura's interpretability, enabled by its hierarchical attention mechanism, offers valuable insights into the factors influencing trial durations, assisting clinicians and researchers in making informed decisions. The model's ability to highlight key features contributing to duration predictions enhances its utility as a decision-support tool in the pharmaceutical industry. In addition to its predictive capabilities, TrialDura marks a significant advancement in applying artificial intelligence to clinical trials. By leveraging state-of-the-art natural language processing techniques and integrating them with structured clinical data, TrialDura not only enhances the accuracy of duration predictions but also deepens the understanding of factors driving trial timelines. This comprehensive approach allows for a more nuanced analysis of clinical trial data, providing stakeholders with actionable insights to inform strategic decision-making and improve the overall efficiency of the drug development process. The implications of TrialDura extend beyond individual trial predictions, offering a framework that can be adapted and scaled to address various challenges in clinical research. As the pharmaceutical industry continues to evolve, the ability to accurately predict and manage trial durations will become increasingly important, making tools like TrialDura indispensable for researchers and decision-makers. By fostering a deeper understanding of trial dynamics and enabling more effective resource allocation, TrialDura has the potential to transform the landscape of clinical trials, ultimately leading to faster and more cost-effective development of new therapies. The code for TrialDura is publicly available at https://github.com/LeoYML/TrialDura.

8 August 2026 in Computer Methods in Applied Mechanics and Engineering
Verified
Journal Article
Closed access
LYLing Yue
Ling Yue
NSNithin Somasekharan
Nithin Somasekharan
TZTingwen Zhang
Tingwen Zhang
YCYadi Cao
Yadi Cao
ZCZhangze Chen
Zhangze Chen
SPShaowu Pan
Shaowu Pan

5 March 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
LYLing Yue
Ling Yue
CKChing-Yun Ko
Ching-Yun Ko
PCPin-Yu Chen
Pin-Yu Chen
SDShimin Di
Shimin Di
SPShaowu Pan
Shaowu Pan
Large language models (LLMs) are evolving from chatbots with limited tool-using capabilities to agentic AI systems that can perform deep research, assist in proposing hypotheses, help design experiments, automate data analysis, and draft scientific reports. However, there are currently two bottlenecks limiting LLMs' real-world impact on the broader scientific research community beyond academic demonstrations: lack of interoperability (repetitive manual tool-integration is required across scenarios) and the need for scalable coordination (unstructured communication and memory become brittle as the number of agents grows). In this Perspective, we argue that the next phase of agentic scientific discovery requires the development of an \emph{ecosystem} of protocol-native agents and tools organized through hierarchies inspired by human society, beyond the current paradigm of a single monolithic ``AI scientist''. We use Model Context Protocol (MCP) as a concrete example of an emerging interoperability layer for scientific tool and context exchange, and we propose three complementary pathways to increase the scaling capabilities of an MCP-native scientific ecosystem by addressing the composability issues: (1) MCP servers for high-value scientific tools maintained by domain experts, (2) automated transformation of existing code repositories into MCP services, and (3) autonomous invention and evolution of new agents and workflows. Finally, we provide a practical roadmap for scaling AI-driven scientific discovery by expanding tool supply and coordination in MCP-native scientific ecosystems.